Nabriva Therapeutics plc (NBRV) Financial Analysis and Rating

Comparison Analysis Based on SEC Data

Company Name Nabriva Therapeutics plc
Industry (SIC) 2834 - Pharmaceutical Preparations
Latest quarterly report 12/31/2021 (filed 3/29/2022)
Revenue $9 million (ranked #311 out of 572 companies in the industry)
Assets $81 million (ranked #418)

Financial Position and Performance (2021)

Compared with industry ratios Change during the quarter

worse

deteriorated
Compared with all industry ratios

worse

Compare with a competitor

Financial Ratios Benchmarking

Finanancial Ratio Comparison of Q4 2021 company ratios
with industry ratios
(28 - Chemicals And Allied Products)
with all industry ratios
Solvency Ratios
Debt ratio 
0.34
0.31
0.34
0.53
Debt-to-equity ratio 
0.52
0.28
0.52
0.75
Interest coverage ratio 
-57.82
-6.63
-57.82
2.84
Liquidity Ratios
Current Ratio 
3.59
5.04
3.59
2.11
Quick Ratio 
2.56
2.94
2.56
1.30
Cash Ratio 
2.14
4.29
2.14
0.92
Profitability Ratios
Profit margin 
-141.1%
-100.7%
-141.1%
4%
ROE (Return on equity), after tax 
-87.9%
-49.6%
-87.9%
-2.2%
ROA (Return on assets) 
-60.3%
-32.6%
-60.3%
0.5%
Activity Ratios
Asset turnover (days) 
854
1260
854
761
Resulting score -0,7 -0,3

Additional Ratios (not used to calculate the resulting score)

Finanancial Ratio Comparison of Q4 2021 company ratios
with industry ratios
(28 - Chemicals And Allied Products)
with all industry ratios
Profitability Ratios
Gross margin 
43.1%
49.3%
43.1%
41.3%
Operating margin (Return on sales) 
-139.2%
-17.5%
-139.2%
9.5%
Activity Ratios
Inventory turnover (days) 
266
116
266
78
EBIT $(13)M
EBITDA $(13)M
Price Ratios
Earnings per Share (basic) $-0.21
Earnings per Share (diluted) $-0.17

Auditor's Conclusion

We have performed a comparative analysis of the balance sheet and income statement of Nabriva Therapeutics plc (hereafter – the "Company") for the year 2021 as submitted to the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Pharmaceutical Preparations" (SIC code 2834). In the analysis, we have compared the key financial ratios of the company with the average (median) values of those ratios calculated for the specific industry sector and for all industries. The averages are calculated using data from the 2021 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have drawn a general conclusion about the quality of the company's financial condition. Calculations and summary conclusions are performed in a computerized manner using software and methodologies developed by ReadyRatios.

As a result of the analysis of the key financial ratios of the company, we have established the following. The financial condition of Nabriva Therapeutics plc in 2021 is worse than the financial condition of half of all companies engaged in the activity "Pharmaceutical Preparations"

This conclusion is supported by a comparison of the Company's financial ratios with average U.S. ratios. The financial position of Nabriva Therapeutics plc is worse than that of most listed companies that submit financial statements to the U.S. Securities and Exchange Commission.

Financial Position and Performance History


Additional Data about Nabriva Therapeutics plc

Closest Competitors

Company USD ($), in Millions
Revenue Assets
Y-mAbs Therapeutics, Inc. 10 213
Morphic Holding, Inc. 10 426
Elite Pharmaceuticals Inc 9 32
Protagonist Therapeutics, Inc. 9 348

See also all industry leaders

Financial Data Source and Analysis Principles

The above is a comparative analysis of the company's financial position and performance. The comparison is based on official financial statements filed with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) (about 10,000 largest publicly traded companies). The comparison is made using the eleven key financial ratios (see table above). The company's financial ratios are compared with the median of the ratios for all companies and for companies in the same industry, as well as to the quartiles of these ratios. Each ratio value is assigned a score between -2 and +2 depending on its position relative to the quartiles (-2 – below the first quartile; -1 – between the first and the second quartile; +1 – between the second and the third quartile; +2 – above the third quartile; 0 – the ratio value deviates from the median by no more than 5% of the difference between the median and the quartile closest to the ratio value). To draw a conclusion from the analysis, the individual scores are weighted equally to produce an overall score ranging from -2 and +2.

much better (+1 - +2incl)
better (from 0.11 to +1incl)
about the same (from -0.11incl to +0.11incl)
worse (from -1incl to -0.11)
much worse (from -2incl to -1)
"Change during the year" calculation

Change during the year is calculated by comparing the resulting score of financial position within the industry with the last year's (quarter's) score. The result of the comparison may be as follows:

significantly improved (positive change of more than 1 point)
improved (positive change of less than 1 point)
unchanged (little or no change in score, no more than 0.11 points)
deteriorated (the score has decreased by less than 1 point during the year)
deteriorated significantly (the score has decreased by more than 1 point during the year)


Please note that this analysis does not indicate that the company's financial position is good or bad, but rather describes it in comparison to other U.S. businesses. For a detailed financial analysis, please use "ReadyRatios Financial Analysis" - load the data into the program>>

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: